Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glutathione arsenoxide
- Development stage
- Phase 1
- Lead developer
- NewSouth Innovations
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
Glutathione arsenoxide (GSAO) is a small molecule anticancer agent and tumor metabolism inhibitor. It targets mitochondrial endomycin, disrupting mitochondrial function in cancer cells, which leads to inhibition of tumor growth. GSAO has been studied for its ability to induce apoptosis and affect various cellular pathways involved in cell cycle regulation, DNA damage response, and metabolic processes[1].
- Other names
- glutathione arsenoxide
02
Targets
ANT1/2/3 (Mitochondrial ADP/ATP translocase)
Beyond the preview
Go deeper on glutathione arsenoxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glutathione arsenoxide.